Drug Profile
Research programme: neoantigen-based cancer immunotherapeutics - Gritstone bio/Immune Design
Alternative Names: ChAdV-srRNA based TSNA vaccine; multi-genome ZVex; ZVex-Neo; ZVexMultiLatest Information Update: 19 Dec 2022
Price :
$50
*
At a glance
- Originator Gritstone Oncology; Immune Design
- Developer Gritstone bio
- Class Cancer vaccines; Immunoproteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 19 Dec 2022 Preclinical development is ongoing in Gastric cancer and Non-small cell lung cancer (Gritstone Bio pipeline, December 2022)
- 13 Dec 2022 Gritstone bio has patent protection for cancer vaccine candidates (GRANITE) and antigen-encoding samRNA vectors in USA
- 28 Oct 2021 No recent reports of development identified for preclinical development in Gastric-cancer in USA (Parenteral)